Prognostic Role of Methylation Status of the MGMT Promoter Determined Quantitatively by Pyrosequencing in Glioblastoma Patients
Dae Cheol Kim, Ki Uk Kim, Young Zoon Kim
J Korean Neurosurg Soc. 2016;59(1):26-36.   Published online 2016 Jan 20     DOI: https://doi.org/10.3340/jkns.2016.59.1.26
Citations to this article as recorded by Crossref logo
Pyrosequencing Analysis of O-6-Methylguanine-DNA Methyltransferase Methylation at Different Cut-Offs of Positivity Associated with Treatment Response and Disease-Specific Survival in Isocitrate Dehydrogenase-Wildtype Grade 4 Glioblastoma
Fábio França Vieira e Silva, Marina Di Domenico, Vito Carlo Alberto Caponio, Mario Pérez-Sayáns, Gisela Cristina Vianna Camolesi, Laura Isabel Rojo-Álvarez, Andrea Ballini, Abel García-García, María Elena Padín-Iruegas, Jose Manuel Suaréz-Peñaranda
International Journal of Molecular Sciences.2024; 25(1): 612.     CrossRef
Cellular Conversations in Glioblastoma Progression, Diagnosis and Treatment
Ali Karimi Sisakht, Mohammad Malekan, Farbod Ghobadinezhad, Seyedeh Negar Mousavi Firouzabadi, Ameneh Jafari, Seyed Mohammad Ali Mirazimi, Banafshe Abadi, Rana Shafabakhsh, Hamed Mirzaei
Cellular and Molecular Neurobiology.2023; 43(2): 585.     CrossRef
Hypomethylation in MTNR1B: a novel epigenetic marker for atherosclerosis profiling using stenosis radiophenotype and blood inflammatory cells
Jee Yeon Kim, Jaroslav Jelinek, Young Ho Lee, Dae Hyun Kim, Keunsoo Kang, Su Hyun Ryu, Hye Rin Moon, Kwangjo Cho, Seo Hee Rha, Jae Kwan Cha, Jean-Pierre J. Issa, Jei Kim
Clinical Epigenetics.2023;[Epub]     CrossRef
Oligodendrocyte Transcription Factor 2 as a Potential Prognostic Biomarker of Glioblastoma: Kaplan-Meier Analysis and the Development of a Binary Predictive Model Based on Visually Accessible Rembrandt Image and Magnetic Resonance Imaging Radiomic Feature
Nan Mei, Yiping Lu, Shan Yang, Shenghong Jiang, Zhuoying Ruan, Dongdong Wang, Xiujuan Liu, Yinwei Ying, Xuanxuan Li, Bo Yin
Journal of Computer Assisted Tomography.2023; 47(4): 650.     CrossRef
DNA methylation status of SHATI/NAT8L promoter in the blood of cigarette smokers
Naotaka Izuo, Hajime Miyanishi, Daisuke Nishizawa, Takuma Fujii, Junko Hasegawa, Naomi Sato, Fumihiko Tanioka, Haruhiko Sugimura, Kazutaka Ikeda, Atsumi Nitta
Neuropsychopharmacology Reports.2023; 43(4): 570.     CrossRef
Bisulfite profiling of the MGMT promoter and comparison with routine testing in glioblastoma diagnostics
Sascha Tierling, Wiebke M. Jürgens-Wemheuer, Alea Leismann, Julia Becker-Kettern, Michael Scherer, Arne Wrede, David Breuskin, Steffi Urbschat, Christoph Sippl, Joachim Oertel, Walter J. Schulz-Schaeffer, Jörn Walter
Clinical Epigenetics.2022;[Epub]     CrossRef
Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter
Michael Lim, Michael Weller, Ahmed Idbaih, Joachim Steinbach, Gaetano Finocchiaro, Raju R Raval, George Ansstas, Joachim Baehring, Jennie W Taylor, Jerome Honnorat, Kevin Petrecca, Filip De Vos, Antje Wick, Ashley Sumrall, Solmaz Sahebjam, Ingo K Mellingh
Neuro-Oncology.2022; 24(11): 1935.     CrossRef
Quantitative Analysis of the MGMT Methylation Status of Glioblastomas in Light of the 2021 WHO Classification
Levin Häni, Monika Kopcic, Mattia Branca, Alessa Schütz, Michael Murek, Nicole Söll, Erik Vassella, Andreas Raabe, Ekkehard Hewer, Philippe Schucht
Cancers.2022; 14(13): 3149.     CrossRef
Molecular and Circulating Biomarkers in Patients with Glioblastoma
Nadia Senhaji, Asmae Squalli Houssaini, Salma Lamrabet, Sara Louati, Sanae Bennis
International Journal of Molecular Sciences.2022; 23(13): 7474.     CrossRef
Prognostic value of test(s) for O6-methylguanine–DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide
Alexandra McAleenan, Claire Kelly, Francesca Spiga, Ashleigh Kernohan, Hung-Yuan Cheng, Sarah Dawson, Lena Schmidt, Tomos Robinson, Sebastian Brandner, Claire L Faulkner, Christopher Wragg, Sarah Jefferies, Amy Howell, Luke Vale, Julian P T Higgins, Kathr
Cochrane Database of Systematic Reviews.2021;[Epub]     CrossRef
MGMTpromoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Systematic Review
Sebastian Brandner, Alexandra McAleenan, Claire Kelly, Francesca Spiga, Hung-Yuan Cheng, Sarah Dawson, Lena Schmidt, Claire L Faulkner, Christopher Wragg, Sarah Jefferies, Julian P T Higgins, Kathreena M Kurian
Neuro-Oncology.2021; 23(9): 1457.     CrossRef
Identifying the optimal cutoff point for MGMT promoter methylation status in glioblastoma
Ngan Nguyen, Jordan Redfield, Matthew Ballo, Madison Michael, Jeffrey Sorenson, Daniel Dibaba, Jim Wan, Glenda Delgado Ramos, Manjari Pandey
CNS Oncology.2021;[Epub]     CrossRef
Extent of MGMT promoter methylation modifies the effect of temozolomide on overall survival in patients with glioblastoma: a regional cohort study
Michael T C Poon, Shivank Keni, Vineeth Vimalan, Chak Ip, Colin Smith, Sara Erridge, Christopher J Weir, Paul M Brennan
Neuro-Oncology Advances.2021;[Epub]     CrossRef
Investigating DNA Methylation of SHATI/NAT8L Promoter Sites in Blood of Unmedicated Patients with Major Depressive Disorder
Hajime Miyanishi, Kyosuke Uno, Mina Iwata, Yuu Kikuchi, Hidenaga Yamamori, Yuka Yasuda, Kazutaka Ohi, Ryota Hashimoto, Kotaro Hattori, Sumiko Yoshida, Yu-ichi Goto, Tomiki Sumiyoshi, Atsumi Nitta
Biological and Pharmaceutical Bulletin.2020; 43(7): 1067.     CrossRef
Posttreatment Effect of MGMT Methylation Level on Glioblastoma Survival
Rikke H Dahlrot, Pia Larsen, Henning B Boldt, Melissa S Kreutzfeldt, Steinbjørn Hansen, Jacob B Hjelmborg, Bjarne Winther Kristensen
Journal of Neuropathology & Experimental Neurology.2019; 78(7): 633.     CrossRef
Biomarkers and therapeutic advances in glioblastoma multiforme
Andrew Octavian Sasmita, Ying Pei Wong, Anna Pick Kiong Ling
Asia-Pacific Journal of Clinical Oncology.2018; 14(1): 40.     CrossRef
Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients
Guoqiang Yuan, Liang Niu, Yinian Zhang, Xiaoqing Wang, Kejun Ma, Hang Yin, Junqiang Dai, Wangning Zhou, Yawen Pan
Journal of Neuro-Oncology.2017; 133(1): 193.     CrossRef
Increased expression of the histone H3 lysine 4 methyltransferase MLL4 and the histone H3 lysine 27 demethylase UTX prolonging the overall survival of patients with glioblastoma and a methylated MGMT promoter
Jinho Kim, Sung-Hun Lee, Ji Hwan Jang, Mee-Seon Kim, Eun Hee Lee, Young Zoon Kim
Journal of Neurosurgery.2017; 126(5): 1461.     CrossRef
DNA methylation/hydroxymethylation in melanoma
Siqi Fu, Haijing Wu, Huiming Zhang, Christine G. Lian, Qianjin Lu
Oncotarget.2017; 8(44): 78163.     CrossRef
The prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients’ survival: a meta-analysis
Hailong Zhao, Shuying Wang, Chengwei Song, Yunhong Zha, Li Li
World Journal of Surgical Oncology.2016;[Epub]     CrossRef